BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30

• 

  Drug Development

  BrainStorm’s ALS Drug NurOwn Flops, But Signs of Efficacy Push Company to Continue R&D

  A Phase III trial of NurOwn® (MSC-NTF cells), BrainStorm Cell Therapeutics’ investigational therapy for amyotrophic lateral sclerosis, did not find a statistically significant difference between the therapy and placebo for improving scores on a revised ALS functional rating scale.

  November 17, 2020

   · 

  3 min read

   · 

  Brandon May
• 

  Business

  Curing Our Kids: Seattle Children’s Launches Next-Gen Therapeutics Non-Profit

  The word “children” may come second in their name, but Seattle Children’s Hospital is proving they truly put children first.

  November 17, 2020

   · 

  9 min read

   · 

  Kate Goodwin
• 

  Deals

  Biopharma Money on the Move: November 11-17

  Find out which biopharma companies are raking in cash this week, as companies from around the globe provide updates on their financing rounds and IPOs.

  November 17, 2020

   · 

  4 min read

   · 

  Kate Goodwin
• 

  Business

  OncoMyx’s Oncolytic Virus Platform Shows Preclinical Efficacy, Boosting Immunotherapy Potential

  Only about one in seven cancer patients today benefit from immunotherapy. OncoMyx aims to increase this number, using a new multi-armed, systemically administered and targeted oncolytic virus.

  November 17, 2020

   · 

  4 min read

   · 

  Gail Dutton
• 

  Policy

  Adamis and Alkermes Eye Adjustments Following Complete Response Letters from FDA

  The two companies received Complete Response Letters from the FDA this week, along with Sanofi.

  November 17, 2020

   · 

  2 min read

   · 

  Krystle Vermes
• 

  Pharm Country

  FDA Delay for BMS’ Liso-cel Likely Kills $9 Celgene CVR Hopes for Investors

  This morning, the pharma giant signaled it will fail to meet a deadline related to $9 per share Contingent Value Rights (CVR) tickets, essentially killing that payment.

  November 17, 2020

   · 

  2 min read

   · 

  Alex Keown
• 

  Genetown

  Pfizer-BioNTech and Moderna’s Vaccines Are Leading the COVID-19 Race. How Do They Compare?

  There are similarities between the two COVID-19 vaccine candidates, and a few differences. Here’s a look.

  November 17, 2020

   · 

  5 min read

   · 

  Mark Terry
• 

  Business

  Warren Buffett Makes Big Bets on Pharma Stocks

  Warren Buffett, one of America’s best-known investors, is backing multiple pharmaceutical companies developing therapies aimed at curbing the ongoing global COVID-19 pandemic.

  November 17, 2020

   · 

  2 min read

   · 

  Alex Keown
• 

  Drug Development

  Bayer’s Finerenone Significantly Reduces CV Outcomes in CKD and T2D, According to New Data

  Finerenone is an oral, non-steroidal selective mineralocorticoid receptor antagonist (MRA).

  November 17, 2020

   · 

  3 min read

   · 

  Brandon May
• 

  Business

  AI in Biopharma: Deep Genomics and BioMarin Forge Pact; InterVenn Raises $34 Million

  There are many examples of how biopharma is leveraging AI and forging partnerships with companies focused on AI for drug development and clinical trials. There have been a few recent AI-based partnerships as well.

  November 17, 2020

   · 

  4 min read

   · 

  Mark Terry